---
figid: PMC7896225__NRR-16-304-g004
figtitle: 'Proposed neuroprotective role of Withaferin A (WA) in the modulation of
  pathways implicated in neurological abnormalities and dysfunctions.Parkinson’s disease
  (PD): WA is a known inhibitor of the Cdc37/Hsp90 complex'
organisms:
- Human immunodeficiency virus
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC7896225
filename: NRR-16-304-g004.jpg
figlink: pmc/articles/PMC7896225/figure/F1/
number: F1
caption: 'Proposed neuroprotective role of Withaferin A (WA) in the modulation of
  pathways implicated in neurological abnormalities and dysfunctions.Parkinson’s disease
  (PD): WA is a known inhibitor of the Cdc37/Hsp90 complex. Inhibition of Cdc37/Hsp90
  has resulted in a decrease of pathological protein LRRK2 in cellular models. WA
  exposure also increased the expression of p62 intracellularly, which could potentially
  be responsible for decreased levels of α-synuclein. WA also rescued low levels of
  dopamine (DA) and homovanillic acid (HVA) to improve motor deficits. Cerebral infarction
  (CI): In vitro WA treatment reduced expression of matrix metalloproteinases (MMPs),
  which mitigate VSMC migration and proliferation. In vivo the PI3K/Akt pathway was
  activated through induced CI, leading to a prevention of apoptosis. Reactive gliosis
  (RG): inhibition of both expression and polymerization of intermediate filaments
  (IFs) by WA led to a decrease in astrocyte reactivity and neuronal apoptosis. Amyotrophic
  lateral sclerosis (ALS): WA induced expression of Hsp25, which led to a decrease
  in mutant superoxide dismutase 1 (SOD1) and a decrease in neuronal apoptosis. Suppression
  of nuclear factor kappa B (NF-κB) by WA is linked to clearance of transactive response
  DNA-binding protein 43 (TDP-43). Human immunodeficiency virus-associated neurological
  dysfunctions (HIV-AND): WA treatment lowered amyloid beta (Aβ) aggregation in SH-APP
  cells. Reduced dendritic beading and cytoplasmic vacuoles were also shown in cells
  treated with WA. Uncertain until further study , leads to , prevents .'
papertitle: Implications of Withaferin A in neurological disorders.
reftext: Natasha Ram, et al. Neural Regen Res. 2021 Feb;16(2):304-305.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8801821
figid_alias: PMC7896225__F1
figtype: Figure
redirect_from: /figures/PMC7896225__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7896225__NRR-16-304-g004.html
  '@type': Dataset
  description: 'Proposed neuroprotective role of Withaferin A (WA) in the modulation
    of pathways implicated in neurological abnormalities and dysfunctions.Parkinson’s
    disease (PD): WA is a known inhibitor of the Cdc37/Hsp90 complex. Inhibition of
    Cdc37/Hsp90 has resulted in a decrease of pathological protein LRRK2 in cellular
    models. WA exposure also increased the expression of p62 intracellularly, which
    could potentially be responsible for decreased levels of α-synuclein. WA also
    rescued low levels of dopamine (DA) and homovanillic acid (HVA) to improve motor
    deficits. Cerebral infarction (CI): In vitro WA treatment reduced expression of
    matrix metalloproteinases (MMPs), which mitigate VSMC migration and proliferation.
    In vivo the PI3K/Akt pathway was activated through induced CI, leading to a prevention
    of apoptosis. Reactive gliosis (RG): inhibition of both expression and polymerization
    of intermediate filaments (IFs) by WA led to a decrease in astrocyte reactivity
    and neuronal apoptosis. Amyotrophic lateral sclerosis (ALS): WA induced expression
    of Hsp25, which led to a decrease in mutant superoxide dismutase 1 (SOD1) and
    a decrease in neuronal apoptosis. Suppression of nuclear factor kappa B (NF-κB)
    by WA is linked to clearance of transactive response DNA-binding protein 43 (TDP-43).
    Human immunodeficiency virus-associated neurological dysfunctions (HIV-AND): WA
    treatment lowered amyloid beta (Aβ) aggregation in SH-APP cells. Reduced dendritic
    beading and cytoplasmic vacuoles were also shown in cells treated with WA. Uncertain
    until further study , leads to , prevents .'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HSP90AA1
  - HSP90B1
  - TRAP1
  - HSP90AB1
  - CDC37
  - APP
  - SUCLA2
  - GTF2H1
  - SQSTM1
  - KHDRBS1
  - NUP62
  - DCTN4
  - MMP1
  - MMP2
  - MMP3
  - MMP7
  - MMP8
  - MMP9
  - MMP10
  - MMP11
  - MMP12
  - MMP13
  - MMP14
  - MMP15
  - MMP16
  - MMP17
  - MMP19
  - MMP20
  - MMP21
  - MMP23B
  - MMP24
  - MMP25
  - MMP26
  - MMP27
  - MMP28
  - HSPB1
  - NFKB1
  - RELA
  - SYT1
  - GORASP1
  - WNK1
  - LRRK2
  - SOD1
  - FUT3
  - TARDBP
  - IGFALS
  - Hsp83
  - Gp93
  - Cdc37
  - ab
  - Appl
  - ref(2)P
  - DCTN4-p62
  - Tfb1
  - Nup62
  - Taf6
  - how
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Mmp1
  - da
  - nAChRalpha2
  - Dif
  - dl
  - Rel
  - wash
  - Lrrk
  - if
  - Sod1
  - TBPH
  - rg
  - ci
  - als
  - conv
  - nAChRalpha1
  - pd
  - Wthaferin A
---
